Sign in

    STERIS plc (STE)

    Financials

    Updated Feb 18, 2025, 5:22 PM UTC
    Income Statement - Metric (Unit, Scale)H1 20199M 2019Q1 2019Q2 2019Q3 2019Q4 2019FY 2019H1 20209M 2020Q1 2020Q2 2020Q3 2020Q4 2020FY 2020H1 20219M 2021Q1 2021Q2 2021Q3 2021Q4 2021FY 2021H1 20229M 2022Q1 2022Q2 2022Q3 2022Q4 2022FY 2022H1 20239M 2023Q1 2023Q2 2023Q3 2023Q4 2023FY 2023H1 20249M 2024Q1 2024Q2 2024Q3 2024Q4 2024FY 2024H1 2025Q1 2025Q2 2025Q3 2025
    Total Revenue [USD, Thousands]1,342,361,395,6451,116,1545,138,701-1,279,5021,328,9121,370,57
    Cost of Goods Sold (COGS) [USD, Thousands]748,831793,052667,5772,920,541-707,072750,121760,238
    SG&A [USD, Thousands]380,651360,518152,0911,252,318-335,626329,298335,45
    R&D [USD, Thousands]27,04425,91325,22103,679-25,57327,03127,358
    D&A [USD, Thousands]152,252140,629134,438565,244-112,698115,255125,913
    Interest Expense [USD, Thousands]36,9438,94736,103144,351-30,38419,66819,094
    Operating Income (EBIT) [USD, Thousands]185,857216,156245,223836,118-185,531219,666245,293
    Net Income [USD, Thousands]115,319142,208-1,002380,079-145,541151,173173,285
    EPS - Basic [USD]1.171.42-0.013.83-1.471.521.71
    EPS - Diluted [USD]1.161.41-0.013.81-1.461.521.7
    Balance Sheet - MetricH1 20199M 2019Q1 2019Q2 2019Q3 2019Q4 2019FY 2019H1 20209M 2020Q1 2020Q2 2020Q3 2020Q4 2020FY 2020H1 20219M 2021Q1 2021Q2 2021Q3 2021Q4 2021FY 2021H1 20229M 2022Q1 2022Q2 2022Q3 2022Q4 2022FY 2022H1 20239M 2023Q1 2023Q2 2023Q3 2023Q4 2023FY 2023H1 20249M 2024Q1 2024Q2 2024Q3 2024Q4 2024FY 2024H1 2025Q1 2025Q2 2025Q3 2025
    Cash and cash equivalents [USD, thousands]213,757195,585207,020207,020-198,328172,195155,178
    Accounts receivable net [USD, thousands]940,331964,0221,008,3151,008,315-892,606923,340915,199
    Inventories net [USD, thousands]821,129855,617674,535674,535-698,587688,933649,558
    Prepaid expenses and other current assets [USD, thousands]198,760203,729174,349174,349-150,973153,401177,918
    Current assets held for sale [USD, thousands]--804,904804,904----
    Total current assets [USD, thousands]2,173,9772,218,9532,869,1232,869,123-1,940,4941,937,8691,897,853
    Property plant and equipment net [USD, thousands]1,743,8581,844,4841,765,1801,765,180-1,834,2161,929,6661,921,733
    Lease right-of-use assets net [USD, thousands]192,219195,413173,201173,201-165,020159,237153,879
    Goodwill [USD, thousands]4,040,2454,111,6834,070,7124,070,712-4,056,7544,151,4374,044,198
    Intangibles net [USD, thousands]3,057,7112,987,2872,119,2822,119,282-2,048,9902,003,6691,923,020
    Other assets [USD, thousands]72,62877,33566,19966,199-63,12760,26767,679
    Total assets [USD, thousands]11,280,63811,435,15511,063,69711,063,697-10,108,60110,242,14510,008,362
    Accounts payable [USD, thousands]293,628276,730251,723251,723-231,720235,070238,298
    Accrued income taxes [USD, thousands]32,25124,88013,64013,640-57,0005,850-
    Accrued payroll and other related liabilities [USD, thousands]135,522178,838164,831164,831-149,372146,575160,785
    Short-term lease obligations [USD, thousands]34,11236,71131,23931,239-29,70530,50932,451
    Short-term indebtedness [USD, thousands]70,93878,43885,93885,938-80,00080,000125,000
    Accrued expenses and other [USD, thousands]306,664318,097319,744319,744-286,563307,479334,586
    Current liabilities held for sale [USD, thousands]--64,01264,012----
    Total current liabilities [USD, thousands]873,115913,694931,127931,127-834,360805,483891,120
    Long-term indebtedness [USD, thousands]3,366,2413,231,0753,120,1623,120,162-2,235,6012,156,1582,038,725
    Deferred income taxes net [USD, thousands]613,451621,071479,688479,688-456,465462,741453,125
    Long-term lease obligations [USD, thousands]162,116162,827145,828145,828-139,362133,148123,717
    Other liabilities [USD, thousands]76,54778,38971,54671,546-72,36874,15373,129
    Total liabilities [USD, thousands]5,091,4705,007,0564,748,3514,748,351-3,738,1563,631,6833,579,816
    Ordinary shares [USD, thousands]4,518,9114,534,2594,543,1764,543,176-4,499,5804,490,9994,404,687
    Retained earnings [USD, thousands]2,045,8972,133,7662,087,6452,087,645-2,178,0872,268,3262,385,664
    Accumulated other comprehensive loss [USD, thousands](386,735)(252,629)(328,657)(328,657)-(323,070)(165,836)(374,250)
    Total shareholders’ equity [USD, thousands]6,178,0736,415,3966,302,1646,302,164-6,354,5976,593,4896,416,101
    Noncontrolling interests [USD, thousands]11,09512,70313,18213,182-15,84816,97312,445
    Total equity [USD, thousands]6,189,1686,428,0996,315,3466,315,346-6,370,4456,610,4626,428,546
    Total liabilities and equity [USD, thousands]11,280,63811,435,15511,063,69711,063,697-10,108,60110,242,14510,008,362
    Cash Flow - Metric (Unit, Scale)H1 20199M 2019Q1 2019Q2 2019Q3 2019Q4 2019FY 2019H1 20209M 2020Q1 2020Q2 2020Q3 2020Q4 2020FY 2020H1 20219M 2021Q1 2021Q2 2021Q3 2021Q4 2021FY 2021H1 20229M 2022Q1 2022Q2 2022Q3 2022Q4 2022FY 2022H1 20239M 2023Q1 2023Q2 2023Q3 2023Q4 2023FY 2023H1 20249M 2024Q1 2024Q2 2024Q3 2024Q4 2024FY 2024H1 2025Q1 2025Q2 2025Q3 2025
    Adjustments for Non-Cash Items [USD, Thousands]319,01112,012256,805738,980-103,808745,704-480,452
    Stock-Based Compensation [USD, Thousands]20,71615,2938,94756,535-11,46020,81215,334
    Changes in Working Capital [USD, Thousands]-116,272-10,61-26,343(147,033)-67,425-46,63827,46
    Capital Expenditures (CapEx) [USD, Thousands]-83,292-118,936-91,497(360,326)-(108,083)-101,892-89,231
    Proceeds from / Repayments of Debt [USD, Thousands]520,673-140,521-99,015121,486-(891,325)-91,72-138,936
    Share Repurchases [USD, Thousands]-489-2,227-325(11,765)-(64,203)-46,422-100,433
    Dividend Payments [USD, Thousands]-51,368-51,378-51,397(200,570)-(51,436)-56,237-56,196
    Net Change in Cash [USD, Thousands]5,143-18,17211,435(1,337)-(8,692)-26,133-17,017
    Revenue by Segment - in Millions of USDH1 20199M 2019Q1 2019Q2 2019Q3 2019Q4 2019FY 2019H1 20209M 2020Q1 2020Q2 2020Q3 2020Q4 2020FY 2020H1 20219M 2021Q1 2021Q2 2021Q3 2021Q4 2021FY 2021H1 20229M 2022Q1 2022Q2 2022Q3 2022Q4 2022FY 2022H1 20239M 2023Q1 2023Q2 2023Q3 2023Q4 2023FY 2023H1 20249M 2024Q1 2024Q2 2024Q3 2024Q4 2024FY 2024H1 2025Q1 2025Q2 2025Q3 2025
    Healthcare870.1916.21,007.83,613.0-901.2944.2976.0
    - Capital Equipment35.4--155.5-26.523.031.1
    - Consumables59.4--251.6-69.872.168.7
    - Service38.2--164.6-32.232.836.6
    AST235.1234.9250.9954.0-249.8256.7258.1
    Life Sciences133.1146.6160.6571.7-128.5127.9136.4
    Dental104.297.9------
    Product Revenue762.3--2,764.0-656.3695.9718.3
    Service Revenue580.0--2,374.7-623.2633.0652.2
    Total Revenue1,342.41,395.61,116.25,138.7-1,279.51,328.91,370.6
    Revenue by Geography - in Millions of USDH1 20199M 2019Q1 2019Q2 2019Q3 2019Q4 2019FY 2019H1 20209M 2020Q1 2020Q2 2020Q3 2020Q4 2020FY 2020H1 20219M 2021Q1 2021Q2 2021Q3 2021Q4 2021FY 2021H1 20229M 2022Q1 2022Q2 2022Q3 2022Q4 2022FY 2022H1 20239M 2023Q1 2023Q2 2023Q3 2023Q4 2023FY 2023H1 20249M 2024Q1 2024Q2 2024Q3 2024Q4 2024FY 2024H1 2025Q1 2025Q2 2025Q3 2025
    Ireland20.419.65122.5582.7-22.222.824.1
    United States992.91,025.458802.543,751.4-946.9979.51,002.6
    Other Foreign Locations329.0350.536291.161,304.6-310.4326.6343.9
    Total Revenue1,342.41,395.6451,116.155,138.7-1,279.51,328.91,370.6
    KPIs - Metric (Unit, Scale)H1 20199M 2019Q1 2019Q2 2019Q3 2019Q4 2019FY 2019H1 20209M 2020Q1 2020Q2 2020Q3 2020Q4 2020FY 2020H1 20219M 2021Q1 2021Q2 2021Q3 2021Q4 2021FY 2021H1 20229M 2022Q1 2022Q2 2022Q3 2022Q4 2022FY 2022H1 20239M 2023Q1 2023Q2 2023Q3 2023Q4 2023FY 2023H1 20249M 2024Q1 2024Q2 2024Q3 2024Q4 2024FY 2024H1 2025Q1 2025Q2 2025Q3 2025
    Backlog in Healthcare segment (millions of USD)457.1449.4-353.8-362.0405.3-
    Backlog in Life Sciences segment (millions of USD)91.185.0-71.4--75.6-